23056-10-2

Basic information

• Product Name: 5-THIOCYANATO-THIAZOL-2-YLAMINE
• Synonyms: 5-thiocyanatothiazol-2-amine;[(2-aMino-1,3-thiazol-5-yl)sulfanyl]forMonitrile;Thiocyanic acid, 2-aMino-5-thiazolyl ester
• CAS NO: 23056-10-2
• Molecular Formula: C₄H₃N₃S₂
• Molecular Weight: 157.22
• Mol File: 23056-10-2.mol
• Article Data: 14

Chemical Properties

• Melting Point: 145 °C (decomp)
• Boiling Point: 369.6°C at 760 mmHg
• Flash Point: 177.3°C
• Appearance: /
• Density: 1.56g/cm³
• Vapor Pressure: 1.17E-05mmHg at 25°C
• Refractive Index: 1.701
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.52±0.10(Predicted)
• CAS DataBase Reference: 5-THIOCYANATO-THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-THIOCYANATO-THIAZOL-2-YLAMINE(23056-10-2)
• EPA Substance Registry System: 5-THIOCYANATO-THIAZOL-2-YLAMINE(23056-10-2)

Safety Data

• Hazardous Substances Data: 23056-10-2(Hazardous Substances Data)

Usage

General Description

5-Thiocyanato-Thiazol-2-ylamine is a chemical compound that falls under the category of organosulfur compounds. These contain carbon-sulfur bonds and include various subcategories such as sulfur-containing heterocycles, as is the case with this specific chemical. 5-Thiocyanato-Thiazol-2-ylamine is used mainly for research purposes in the field of chemistry. It may also find applications in pharmaceutical research for the production of drugs, as several thiazol-2-ylamine derivatives are known to have medicinal properties. Its exact properties, including toxicity, reactivity, and environmental impact, would depend on its specific formulation and on the other compounds it is combined with.

InChI:InChI=1/C4H3N3S2/c5-2-8-3-1-7-4(6)9-3/h1H,(H2,6,7)

Upstream product

• 96-50-4 2-thiazolylamine 
• 1147550-11-5 ammonium thiocyanate 
• 333-20-0 potassium thioacyanate 
• 61296-22-8 5-bromothiazol-2-amine hydrobromide 
• 540-72-7 sodium thiocyanide 
• 3034-22-8 5-bromo-2-aminothiazole 
• 163276-49-1 1-thiocyanatopyrrolidine-2,5-dione 

Downstream Products

• 36016-97-4 2-acetamino-5-thiocyanatothiazole 
• 91059-77-7 N-(5-thiocyanato-thiazol-2-yl)-benzamide 
• 37469-45-7 phenylpropynoic acid 5-thiocyanato-thiazol-2-ylamide 
• 116636-52-3 2-Ethoxycarbonylamino-5-thiocyanato-thiazole 
• 224436-97-9 2-amino-5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-thiazole 
• 1001419-49-3 C₁₃H₁₁N₃OS₂ 
• 859524-83-7 1,1-dicyclohexyl-3-(5-thiocyanatothiazol-2-yl)urea 
• 745074-48-0 5-(2-amino-thiazol-5-ylsulfanylmethyl)-2,3-dimethyl-benzoic acid methyl ester 

Relevant articles and documents

Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13

Genetic depletion of cyclin-dependent kinase 12 (CDK12) or selective inhibition of an analog-sensitive CDK12 reduces DNA damage repair gene expression, but selective inhibition of endogenous CDK12 is difficult. Here, we report the development of MFH290, a novel cysteine (Cys)-directed covalent inhibitor of CDK12/13. MFH290 forms a covalent bond with Cys-1039 of CDK12, exhibits excellent kinome selectivity, inhibits the phosphorylation of serine-2 in the C-terminal domain (CTD) of RNA-polymerase II (Pol II), and reduces the expression of key DNA damage repair genes. Importantly, these effects were demonstrated to be CDK12-dependent as mutation of Cys-1039 rendered the kinase refractory to MFH290 and restored Pol II CTD phosphorylation and DNA damage repair gene expression. Consistent with its effect on DNA damage repair gene expression, MFH290 augments the antiproliferative effect of the PARP inhibitor olaparib.

INHIBITORS OF CYCLIN-DEPENDENT KINASES

The present invention provides novel compounds of Formulae (I'), (I), (II'), and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The compounds of the invention may further act as HDAC inhibitors.